Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Ifinatamab Deruxtecan Earns FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

August 18th 2025

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

August 18th 2025

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

Nirogacestat Wins EU Approval for Progressing Desmoid Tumors

August 18th 2025

The European Commission approved nirogacestat for the treatment of progressing desmoid tumors requiring systemic treatment.

Adjuvant Atezolizumab Boosts DFS, OS in MIBC After Positive MRD Test

August 18th 2025

Adjuvant atezolizumab improved DFS and OS after a positive Signatera MRD test in muscle-invasive bladder cancer.

Phase 2/3 Trial Further Evaluates Ficerafusp Alfa With Pembrolizumab in HPV– Head and Neck Cancer

August 18th 2025

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC

August 15th 2025

Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.

Dr Schetelig on Challenges Assessing Haploidentical vs Mismatched Transplantation in AML/ALL/MDS

August 15th 2025

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

SHR-A1811 Monotherapy Generates Similar pCR Rate as PCbHP in HER2+ Breast Cancer

August 14th 2025

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma

August 14th 2025

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

August 14th 2025

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC

August 14th 2025

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Dr Bedke on the Safety Profile of Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 13th 2025

Jens Bedke, MD, discusses the safety of enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma.

Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma

August 13th 2025

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases

August 13th 2025

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Dr Ansley on the Role of Elacestrant in ER+/HER2– Advanced Breast Cancer

August 12th 2025

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Relacorilant Plus Nab-Paclitaxel May Serve As New Standard of Care in Platinum-Resistant Ovarian Cancer

August 12th 2025

Domenica Lorusso, MD, PhD, discusses the use of relacorilant plus nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.

iPETcertum Receives FDA Clearance for Assisting in PET, PET-CT/MRI Scans for Patients With Cancer and Suspicious Lesions

August 12th 2025

The FDA has cleared iPETcertum for PET and PET-CT/MRI scan enhancement in patients with cancer and suspicious lesions.

Perioperative Enfortumab Vedotin Plus Pembrolizumab Displays Positive Top-Line Data in Muscle-Invasive Bladder Cancer

August 12th 2025

Perioperative enfortumab vedotin plus pembrolizumab significantly extended survival vs surgery alone in MIBC.

Expansion of BTK and BCL2 Inhibitors in CLL Requires Close Attention to Safety, Sequencing Considerations

August 12th 2025

Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.

Dr Ghia on the Rationale for Evaluating Pirtobrutinib in Relapsed/Refractory CLL

August 11th 2025

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.